NASDAQ · Biotechnology

Protara Therapeutics, Inc. (TARA) Stock

$2.72 +2.45% NASDAQ: TARA Healthcare

Valuation

MetricValue
Price$2.72
Market Cap$152.59M
P/E Ratio-1.99
P/B Ratio1.02
P/S Ratio0.00
EPS (TTM)$-1.34
52-Week High$7.82
52-Week Low$2.54
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-41.72%
ROA-39.76%
ROCE-47.18%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio14.55

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-47.0M$-67.0M$-44.0M$-49.0M$-65.0M
Net Profit$-47.0M$-66.0M$-40.0M$-45.0M$-57.0M
EPS$-4.20$-5.86$-3.57$-2.17$-1.34
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$173.0M$113.0M$79.0M$181.0M$209.0M
Total Liabilities$11.0M$11.0M$11.0M$14.0M$13.0M
Cash$36.0M$24.0M$40.0M$163.0M$50.0M
Borrowings$7.0M$6.0M$5.0M$4.0M$3.0M

Latest News

What Makes Protara Therapeutics (TARA) a New Buy Stock Zacks · Jul 21, 2026 Protara Therapeutics CMO Leonardo Viana Nicacio Resigns MT Newswires · Jun 30, 2026 Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight PR Newswire · Jun 23, 2026 Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million Motley Fool · May 31, 2026 Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating MT Newswires · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-35.0M$-26.0M$-38.0M$-36.0M$-56.0M
Investing Cash Flow$-99.0M$15.0M$53.0M$19.0M$-140.0M
Financing Cash Flow$0$0$0$4.0M$0
Net Cash Flow$-133.0M$-12.0M$15.0M$123.0M$-113.0M
Free Cash Flow$-35.0M$-27.0M$-38.0M$-36.0M$-56.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.12
EV / EBITDA-1.97
FCF Yield-42.94%
Quick Ratio10.97
Interest Coverage0.00
Return 1Y19.17%
Return 3Y37.88%
Return 5Y-51.77%

Ownership

Insiders Held2.42%
Institutions Held81.11%
Institutions Float Held83.13%
Institutional HolderSharesReport Date
Janus Henderson Group PLC5,207,0112026-03-31
Blackrock Inc.3,394,9682026-03-31
Velan Capital Investment Management LP2,834,6522026-03-31
Millennium Management Llc2,831,2082026-03-31
Blackstone Inc2,265,5142026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CDXSCodexis, Inc. $1.37 +0.92% -4.05 $147.63M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%
IVVDInvivyd, Inc. $0.73 +4.10% -2.08 $214.80M 0.00%
MDWDMediWound Ltd. $12.55 +1.05% -8.45 $161.21M 0.00%
NTHINeOnc Technologies Holdings, Inc. $2.78 +9.88% -1.22 $72.09M 0.00%

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc. is led by CEO Jesse Shefferman, employs 28 people, headquartered in US, publicly traded since 2014.

Protara Therapeutics, Inc. (TARA) stock trades at $2.72 with a market capitalization of $152.59M. The stock is valued at a price-to-earnings (P/E) ratio of -1.99, price-to-book of 1.02, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.54 and $7.82, and currently trades 65.2% below its 52-week high.

On profitability, Protara Therapeutics, Inc. generates a return on equity (ROE) of -41.72%, return on capital employed of -47.18%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides